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COVID [1]. We have the following comments and concerns. 
The comprehensive review lacks discussing a number of CNS and PNS manifestations of 
neuro-COVID, which should be additionally considered by those involved in the management 
of COVID-19 patients. There is increasing evidence that that the infection with SARS-CoV2 
may also cause CNS disorders such as myoclonus-ataxia syndrome, acute, disseminated 
encephalomyelitis (ADEM), limbic encephalitis, psychosis, intracerebral bleeding, sinus 
venous thrombosis, vasoconstriction syndrome, optic neuritis, or cerebral vasculitis [2]. 
Ischemic stroke may not only be due to hypercoagulability or sinus venous thrombosis, but 
also due to heart failure or arrhythmias, particularly atrial fibrillation. PNS disorders not 
addressed in the review were myasthenia, single or multiple cranial nerve palsies, and 
trigeminal neuralgia.  
Missing is a discussion about myositis and dermatomyositis as a manifestation of 
neuro-COVID. Though there is mentioning that the skeletal muscle can be damaged by the 
virus, it is not addressed that the infection may cause viral myositis, which may clinically 
manifest as muscle weakness, myalgia, generalised fatigue, or exercise intolerance. 
Mentioning myositis is crucial as it has been reported to occur in 11-50% of the cases [3] and 
requires analgesic, anti-inflammatory, or immune-modulating treatment and physiotherapy.  
Missing in the review are the neurological complications of drugs given to treat the viral 
infection. A number of agents applied for the treatment of COVID-19 are neurotoxic. 
Differentiating primary manifestations of the viral infection from side effects of the 
treatment is crucial as most of these neurological side effects disappear with discontinuation 
of the causative agent. Neurotoxic drugs frequently applied for the treatment of COVID-19 
include chloroquine, remdesivir/lopinavir, azithromycin, and tocilizumab. From chloroquine 
it is known that it can trigger myopathy or myasthenic syndrome [4]. Remdesivir, lopinavir, 
and ritonavir may occasionally trigger myopathy or rhabdomyolysis. Azithromycin may 
induce rhabdomyolysis. Tocilizumab is known for muscle aching and muscle cramps as rare 
side effects. Steroids may induce mitochondrial myopathy [4]. Patients requiring ICU 
treatment may develop critical ill neuropathy or myopathy.  
Missing in the review are the neurological complications of primary involvement of 
the heart and vessels in the SARS-CoV-2 infection. It is well appreciated that SARS-CoV-2 may 
go along with myocarditis [5]. Complications of myocarditis may not only be heart failure but 
also conduction defects or arrhythmias, including atrial fibrillation. From heart failure or 
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arrhythmias it is known that they may be complicated by cardio-embolic events, including 
ischemic stroke. Thus it is crucial to investigate patients with COVID-19 cardiologically if CNS 
abnormalities, particularly embolic stroke, occur. 
There is also no discussion about neurological manifestations as the initial 
manifestation of COVID-19. Knowing that COVID-19 can start with CNS/PNS disease prior to 
manifestations in the lungs or other organs is crucial not to overlook the ongoing infection 
but also to prevent the further spreading of the pandemic.  
Overall, the review has a number of limitations, which should be addressed to further 
strengthen the results and discussion. Neurological involvement in COVID-19 is evidently 
broader than anticipated and neurological manifestations may be the initial manifestation of 
the infection in some cases.  
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